Blackbaud Q3 Earnings Beat Doesn't Alter WAIT Thesis

What happened

Blackbaud reported Q3 non-GAAP EPS of $1.36, beating consensus of $1.32 and up from $1.10 a year ago, but the modest beat is largely explained by cost discipline and share buybacks rather than revenue acceleration. Organic growth remained in the expected mid-single-digit range, consistent with the company's 2025 guidance of 4.5–5.4%, and no material change in customer retention or pricing power was disclosed. The deep value analysis already anticipated similar performance, so the news offers little incremental information beyond confirming execution. Meanwhile, the core risks—pricing fatigue on remaining renewal cohorts, high net leverage at ~2.45x, and heavy reliance on debt-funded buybacks—remain unresolved. As a result, the earnings beat does not improve the risk-reward enough to justify a more constructive stance.

Implication

Investors should interpret the Q3 beat as confirmation of steady execution rather than a catalyst for re-rating. The company continues to generate mid-30s EBITDA margins and high free cash flow, but the equity story hinges on sustaining pricing-driven growth and aggressive buybacks despite rising interest expense and covenant constraints. With the stock near $55, the margin of safety remains thin relative to our $50 attractive entry, and upside to the $65 base case is largely priced in. We recommend monitoring the next quarterly report for 2026 guidance and any signs of renewal pushback or leverage deterioration. Until then, maintaining discipline and waiting for a lower entry is prudent, as the balance between risk and reward has not shifted materially.

Thesis delta

The investment thesis is unchanged: Blackbaud is a solid cash-flow compounder but offers limited margin of safety at current prices. The Q3 earnings beat reinforces the base case of ~5% organic growth and stable margins, yet it does not alleviate concerns about pricing fatigue, high leverage, and execution risk. We maintain our WAIT rating with an attractive entry of $50 and will reassess if organic growth sustains above 5% and net leverage trends below 2.0x for two consecutive quarters.